The principle behind this strategy is that estrogen antagonist tamoxifen blocks the estrogen receptor and therefore inhibition of estrogen-induced growth of breast cancer cells followed by chemotherapy that induces cytotoxicity. This evidence concerns the gene ESR1 and breast cancer.